Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe

Table 2 Lipid profiles at baseline, 4, 8 and 12 weeks after randomization

	Rosuvastatin 10 mg/day
	Baseline	4	8	12	12 weeks - baseline
T-Cho (mg/dL)	168.0 ± 17.4	145.5 ± 18.8^‡	148.8 ± 20.6^‡	147.5 ± 22.0^‡	−20.5 ± 18.3
LDL-C (mg/dL)	88.5 ± 12.9	68.0 ± 13.9^‡	65.3 ± 18.0^‡	67.9 ± 17.0^‡	−20.3 ± 15.3
HDL-C (mg/dL)	46.4 ± 11.6	47.8 ± 10.3	51.0 ± 10.3*	51.5 ± 12.1*	4.6 ± 5.9^†
TG (mg/dL)	165.4 ± 78.9	148.8 ± 78.8	162.3 ± 86.1	140.6 ± 80.7	−21.0 ± 66.1
LDL-C/HDL-C ratio	2.05 ± 0.73	1.51 ± 0.54*	1.33 ± 0.45^‡	1.39 ± 0.49^‡	−0.57 ± 0.43
	Rosuvastatin 2.5 mg/day + ezetimibe 10 mg/day
T-Cho (mg/dL)	164.0 ± 23.3	134.7 ± 18.4^‡	137.5 ± 24.5^‡	138.5 ± 19.36^‡	−23.5 ± 17.2
LDL-C (mg/dL)	84.3 ± 14.5	62.3 ± 12.2^‡	62.6 ± 15.3^‡	62.9 ± 11.7^‡	−21.9 ± 14.4
HDL-C (mg/dL)	49.9 ± 12.2	51.0 ± 10.0	51.7 ± 11.0	51.0 ± 9.1	−0.0 ± 6.7
TG (mg/dL)	149.4 ± 103.9	106.7 ± 36.1*	115.7 ± 41.7	123.3 ± 50.0	−7.8 ± 52.8
LDL-C/HDL-C ratio	1.76 ± 0.41	1.26 ± 0.34^‡	1.22 ± 0.24^‡	1.27 ± 0.30^‡	−0.46 ± 0.27

Data are presented as mean ± standard deviation. T-Cho, total cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.
*p < 0.05 versus baseline; ^†p < 0.05 versus rosuvastatin 2.5 mg/day + ezetimibe 10 mg/day; ^‡p < 0.0001 versus baseline.

ISSN: 1476-511X